EA200700035A1 - Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders - Google Patents

Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders

Info

Publication number
EA200700035A1
EA200700035A1 EA200700035A EA200700035A EA200700035A1 EA 200700035 A1 EA200700035 A1 EA 200700035A1 EA 200700035 A EA200700035 A EA 200700035A EA 200700035 A EA200700035 A EA 200700035A EA 200700035 A1 EA200700035 A1 EA 200700035A1
Authority
EA
Eurasian Patent Office
Prior art keywords
epilepsy
treatment
sorders
sulphate
sulfamide derivatives
Prior art date
Application number
EA200700035A
Other languages
English (en)
Other versions
EA013685B1 (ru
Inventor
Дэвид Ф. Маккомси
Майкл Н. Паркер
Ален Б. Рейтц
Брюс Э. Марьянофф
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972935&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA200700035A1 publication Critical patent/EA200700035A1/ru
Publication of EA013685B1 publication Critical patent/EA013685B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

Настоящее изобретение относится к новым сульфамидным и сульфаматным производным, фармацевтическим композициям, их содержащим, и к их применению для лечения эпилепсии и родственных расстройств.
EA200700035A 2004-06-16 2005-06-16 Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных расстройств EA013685B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58017804P 2004-06-16 2004-06-16
PCT/US2005/021513 WO2006007435A1 (en) 2004-06-16 2005-06-16 Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders

Publications (2)

Publication Number Publication Date
EA200700035A1 true EA200700035A1 (ru) 2007-06-29
EA013685B1 EA013685B1 (ru) 2010-06-30

Family

ID=34972935

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700035A EA013685B1 (ru) 2004-06-16 2005-06-16 Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных расстройств

Country Status (22)

Country Link
US (1) US8084490B2 (ru)
EP (1) EP1768970B1 (ru)
JP (2) JP4884378B2 (ru)
CN (1) CN101006072B (ru)
AR (2) AR049398A1 (ru)
AU (1) AU2005262496B2 (ru)
BR (1) BRPI0512242A (ru)
CA (1) CA2570606C (ru)
CR (1) CR8858A (ru)
EA (1) EA013685B1 (ru)
EC (1) ECSP067093A (ru)
ES (1) ES2573844T3 (ru)
IL (1) IL180108A (ru)
MX (1) MXPA06014934A (ru)
MY (1) MY147767A (ru)
NI (1) NI200600306A (ru)
NO (1) NO20070081L (ru)
NZ (1) NZ552056A (ru)
TW (1) TWI361691B (ru)
UA (1) UA91680C2 (ru)
WO (1) WO2006007435A1 (ru)
ZA (1) ZA200700430B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA010977B1 (ru) * 2004-08-24 2008-12-30 Янссен Фармацевтика Н.В. Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058393A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo - fusionados de sulfamida para modificacion de la enfermedad / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20090182141A1 (en) * 2008-01-07 2009-07-16 Ahmed Abdel-Magid Process for the preparation of sulfamide derivatives
CN101981019A (zh) * 2008-03-26 2011-02-23 詹森药业有限公司 用于制备苯并稠合杂芳基氨基磺酸盐的方法和n-((2s)-6-氯-2,3-二氢-1,4-苯并二噁英-2基)甲基-磺酰胺的晶体形式
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
MX2010010597A (es) * 2008-03-26 2010-10-25 Janssen Pharmaceutica Nv Procesos para la preparacion de derivados de dioxina benzofusionados.
EP2271638B1 (en) 2008-04-29 2011-08-31 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
AU2009242092A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
WO2009133109A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011047796A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013045681A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Improved process for the preparation of sulfamide derivatives
JP2014528953A (ja) * 2011-09-29 2014-10-30 ヤンセン ファーマシューティカ エヌ．ベー． スルファミド誘導体の調製プロセス
WO2014140220A1 (en) 2013-03-13 2014-09-18 Janssen Pharmaceutica, N.V. Process for the preparation of (2,3-dihydro-benzo[b][1,4]dioxin-2-yl) methanol derivatives
EP3079686B1 (en) 2013-12-12 2018-10-24 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
JP6311025B2 (ja) 2013-12-12 2018-04-11 バイオ−ファーム ソリューションズ カンパニー リミテッド 痛症を治療又は緩和するためのスルファメート誘導体化合物
CN106456599B (zh) 2013-12-12 2019-05-14 比皮艾思药物研发有限公司 用于治疗或减轻疼痛的氨基磺酸酯衍生化合物
USD827368S1 (en) 2015-09-17 2018-09-04 Traeger Pellet Grills, Llc Grill handle towel bar assembly

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480663A (en) * 1892-08-09 William h
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (ru) * 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
TW274550B (ru) * 1992-09-26 1996-04-21 Hoechst Ag
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
RU2139875C1 (ru) 1993-12-23 1999-10-20 Орто Фармасьютикал Корпорейшн Сульфаматы псевдофруктопиранозы и фармацевтическая композиция на их основе
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
JPH11501619A (ja) * 1995-02-15 1999-02-09 ベアーズデン バイオ，インコーポレイテッド アルキルカルボキシアミノ酸−カイネートレセプターのモジュレーター
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
KR19990071666A (ko) 1995-11-30 1999-09-27 이경하 술파미드 유도체
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5841399A (en) 1996-06-28 1998-11-24 Alliedsignal Inc. Fault detection and exclusion used in a global positioning system GPS receiver
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
ES2184127T3 (es) 1996-06-28 2003-04-01 Ortho Mcneil Pharm Inc Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
RO120771B1 (ro) 1996-08-14 2006-07-28 G.D. Searle & Co. Formă cristalină b a 4-(5-metil-3-fenilizoxazol-4-il) benzensulfonamidei
ES2241055T3 (es) 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
ES2187795T3 (es) 1996-10-08 2003-06-16 Ortho Mcneil Pharm Inc Derivados de anticonvulsivos utiles en el tratamiento del dolor neuropatico.
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5856529A (en) * 1996-12-10 1999-01-05 Bristol-Myers Squibb Company Benzofuran and dihydrobenzofuran melatonergic agents
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
DE69827149T2 (de) * 1997-08-15 2006-03-09 Fairbanks, Carolyn Ann, Rochester Agmatin für die behandlung neuropathischer schmerzen
DE19742508A1 (de) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
SK9362000A3 (en) * 1997-12-19 2001-09-11 Bayer Ag Carboxyl substituted chroman derivatives useful as beta-3-adrenoreceptor agonists
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (ru) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтическая композиция (варианты) и способ ее приготовления
EP0966967A3 (en) 1998-05-29 2000-05-31 Eli Lilly And Company Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL144406A0 (en) * 1999-01-19 2002-05-23 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in treating cluster headaches
WO2000042995A2 (en) 1999-01-21 2000-07-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating transformed migraine
EP1158973B1 (en) 1999-02-24 2005-05-04 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
WO2000061140A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
NZ514810A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering lipids
CA2372806A1 (en) 1999-05-04 2000-11-09 Keith R. Edwards Intravenous valproate for acute treatment of migraine headache
EP2305226B1 (en) 1999-06-14 2015-05-06 Vivus, Inc. Combination therapy for the treatment of sleep apnea associated with obesity
BRPI0013439B8 (pt) 1999-08-20 2021-07-06 Ortho Mcneil Pharm Inc composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE60118206T2 (de) * 2000-07-07 2006-12-14 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6627653B2 (en) * 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
JP4181408B2 (ja) * 2001-01-30 2008-11-12 メルク エンド カムパニー インコーポレーテッド 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類
EP1397136A1 (en) 2001-05-25 2004-03-17 Queen's University At Kingston Heterocyclic beta-aminoacids and their use as anti-epileptogenic agents
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
WO2004092216A1 (en) 2003-04-15 2004-10-28 Trangene S.A. Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer
JP4373343B2 (ja) 2003-04-16 2009-11-25 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
JPWO2004093912A1 (ja) 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7569604B2 (en) 2004-06-22 2009-08-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
MX2007001120A (es) 2004-07-28 2007-03-15 Janssen Pharmaceutica Nv Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa.
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
EA010977B1 (ru) * 2004-08-24 2008-12-30 Янссен Фармацевтика Н.В. Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191474A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
TW200738669A (en) 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
TW200812574A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20090182141A1 (en) * 2008-01-07 2009-07-16 Ahmed Abdel-Magid Process for the preparation of sulfamide derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
CN101981019A (zh) 2008-03-26 2011-02-23 詹森药业有限公司 用于制备苯并稠合杂芳基氨基磺酸盐的方法和n-((2s)-6-氯-2,3-二氢-1,4-苯并二噁英-2基)甲基-磺酰胺的晶体形式
MX2010010597A (es) 2008-03-26 2010-10-25 Janssen Pharmaceutica Nv Procesos para la preparacion de derivados de dioxina benzofusionados.
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
PE20110060A1 (es) * 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida

Also Published As

Publication number Publication date
IL180108A0 (en) 2007-05-15
NO20070081L (no) 2007-02-26
TW200611702A (en) 2006-04-16
CN101006072B (zh) 2011-10-19
AU2005262496A1 (en) 2006-01-19
MXPA06014934A (es) 2007-08-21
AR049398A1 (es) 2006-07-26
CA2570606C (en) 2013-04-30
AU2005262496B2 (en) 2011-10-20
NI200600306A (es) 2007-11-27
AR091400A2 (es) 2015-02-04
JP2011246472A (ja) 2011-12-08
JP5416740B2 (ja) 2014-02-12
US8084490B2 (en) 2011-12-27
NZ552056A (en) 2010-08-27
ZA200700430B (en) 2008-07-30
WO2006007435A1 (en) 2006-01-19
EP1768970A1 (en) 2007-04-04
EP1768970B1 (en) 2016-03-09
UA91680C2 (ru) 2010-08-25
MY147767A (en) 2013-01-31
EA013685B1 (ru) 2010-06-30
ES2573844T3 (es) 2016-06-10
CA2570606A1 (en) 2006-01-19
US20060041008A1 (en) 2006-02-23
CR8858A (es) 2009-01-14
BRPI0512242A (pt) 2008-02-19
TWI361691B (en) 2012-04-11
IL180108A (en) 2015-10-29
JP2008503487A (ja) 2008-02-07
ECSP067093A (es) 2007-01-26
JP4884378B2 (ja) 2012-02-29
CN101006072A (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
ITRM20050265A1 (it) Protesi modulare perfezionata per osteosintesi, in particolare per l'osteosintesi dell'omero.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
EA200702253A1 (ru) Фармацевтическая композиция
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
JO2686B1 (en) Vehicles
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
ATE527243T1 (de) Calciumkanal-antagonisten vom typ chinazolinon t
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU